Cabaletta Bio Inc Sustainability Reports
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00MJ3BKX1
3 reports from 2022 to 2024
Company Profile
A clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
Reports
3 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
